Trial Profile
Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2021
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 30 Apr 2019 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 New trial record